Table 2.

Pharmacokinetic characteristics of the DOACs

CharacteristicDabigatran, %Rivaroxaban, %Apixaban, %Edoxaban, %Betrixaban, %
Hepatic metabolism39,52  None 18 (CYP3A4/CYP3A5) 25 (CYP3A4/CYP3A5) <4 <1 
p-gp substrate39,52  Yes Yes Yes Yes Yes 
Oral bioavailability39,52  6-7 66 50 62 34 
Renal elimination39,52  80 36 27 50 5-7 
CharacteristicDabigatran, %Rivaroxaban, %Apixaban, %Edoxaban, %Betrixaban, %
Hepatic metabolism39,52  None 18 (CYP3A4/CYP3A5) 25 (CYP3A4/CYP3A5) <4 <1 
p-gp substrate39,52  Yes Yes Yes Yes Yes 
Oral bioavailability39,52  6-7 66 50 62 34 
Renal elimination39,52  80 36 27 50 5-7 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal